National Institutes of Health, a Component of the US Dept. of Health & Human Services

The State University of New York

Path, Inc.

The United States of America As Represented by the Department of Health

International Aids Vaccine Initiative

Charles Richter King

Lance A Liotta

Patricia Schriver Steeg

Jonathan Lovell

Shuai Shao

Jumin Geng

Wei-Chiao Huang

Shwu-Maan Lee

Sanjay K Phogat

Wayne C Koff

Simon Hoffenberg

Denise Wagner

The present disclosure provides nanostructures (e.g., monolayer or bilayer nanostructures) comprising porphyrins with cobalt chelated thereto such that the cobalt metal resides within monolayer or bilayer in the porphyrin macrocycle. The nanostructures can have presentation molecules comprising epitopes from microorganisms with a histidine tag attached thereto, such that at least a part of the his-tag is within the monolayer or bilayer and coordinated to the cobalt metal core and the presentation molecules are exposed to the outside of the nanostructures. The nanostructures can further comprise a cargo. The nanostructures can be used to deliver the cargo to an individual.

Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags

The present disclosure provides nanostructures (e.g., monolayer or bilayer nanostructures) comprising porphyrins with cobalt chelated thereto such that the cobalt metal resides within monolayer or bilayer in the porphyrin macrocycle. The nanostructures can have presentation molecules with a histidine tag attached thereto, such that at least a part of the his-tag is within the monolayer or bilayer and coordinated to the cobalt metal core and the presentation molecules are exposed to the outside of the nanostructures. The nanostructures can further comprise a cargo. The nanostructures can be used to deliver the cargo to an individual.

The present application relates to a novel HIV-1 envelope glycoprotein which may be utilized as an HIV-1 vaccine immunogen, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.

HIV-1 envelope glycoprotein

Human nm DNA and protein is disclosed as well as antiodies which recognize human nm protein. The DNA and antibodies may be used to detect nm in human tumors to predict the malignancy potential of such tumors.

Production and use of human nm23 protein and antibodies therefor

Human nm23 DNA and protein is disclosed as well as antibodies which recognize human nm23 protein. The DNA and antibodies may be used to detect nm23 in human tumors to predict the malignancy potential of such tumors.

Growing community of inventors

Washington, DC, United States of America

Charles Richter King